##plugins.themes.academic_pro.article.main##

Abstract

Lung cancer remains a significant global health concern, characterized by uncontrolled cell proliferation and metastatic potential. This study delves into the intricate the correlation between oxidative stress and lung cancer., as well as the potential of paclitaxel as a treatment option. We explore the enzymatic activity of GST, CAT, and MDA in lung cancer patients and a control group, considering their smoking status. Additionally, we investigate the impact of paclitaxel on reactive oxygen species (ROS) production in a malignant cell line. The results demonstrate significant variations in enzymatic activity and ROS induction in lung cancer patients, emphasizing the importance of these factors in the disease's progression. The findings shed light on the potential of paclitaxel as an agent for ROS modulation in lung cancer therapy, providing valuable insights for improved treatment strategies and enhanced patient outcomes

Keywords

lung cancer Oxidative stress Paclitaxel

##plugins.themes.academic_pro.article.details##

How to Cite
Prof. Dr. Firas A. Hassan. (2023). Measurements of enzymes (MDA, CAT, GST) Level in sera of lung cancer in Iraqi patients and the relation with taxol drugs . Texas Journal of Medical Science, 23, 37–43. https://doi.org/10.62480/tjms.2023.vol23.pp37-43

References

  1. A. S. G. Abdel-Salam, M. Mollazehi, D. Bandyopadhyay, A. M. Malki, Z. Shi, and H. Zayed,
  2. “Assessment of lung cancer risk factors and mortality in Qatar: A case series study,” Cancer Rep., vol. 4, no.
  3. , pp. 1–7, 2021, doi: 10.1002/cnr2.1302.
  4. M. Zalewska-Ziob et al., “Activity of Antioxidant Enzymes in the Tumor and Adjacent
  5. Noncancerous Tissues of Non-Small-Cell Lung Cancer,” Oxid. Med. Cell. Longev., vol. 2019, 2019, doi:
  6. 1155/2019/2901840.
  7. J. Kruk, H. Y. Aboul-Enein, A. Kładna, and J. E. Bowser, “Oxidative stress in biological systems
  8. and its relation with pathophysiological functions: the effect of physical activity on cellular redox
  9. homeostasis,” Free Radic. Res., vol. 53, no. 5, pp. 497–521, 2019, doi: 10.1080/10715762.2019.1612059.
  10. B. Salehi et al., “Antioxidants: Positive or negative actors?,” Biomolecules, vol. 8, no. 4, pp. 1–11,
  11. , doi: 10.3390/biom8040124.
  12. F. Yahya, F. Sfouq, and E. El, “Fulwah Yahya Alqahtani,” vol. 44, 2019, doi:
  13. 1016/bs.podrm.2018.11.001.
  14. Y. Ma et al., “Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy,” vol. 9,
  15. no. March, pp. 1–17, 2021, doi: 10.3389/fcell.2021.626910.
  16. J. Sharifi-rad et al., “Review Article Paclitaxel : Application in Modern Oncology and
  17. Nanomedicine- Based Cancer Therapy,” vol. 2021, no. May, 2021.
  18. A. S. K. A. L. Khafaji, I. M. Hade, M. A. A. L. Naqqash, and G. O. Alnefaie, “Potential effects of
  19. miR ‑ 146 expression in relation to malondialdehyde as a biomarker for oxidative damage in patients with
  20. breast cancer,” pp. 1–9, 2023, doi: 10.3892/wasj.2023.187.
  21. Z. G. Zheng et al., “Hydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic
  22. obstructive pulmonary disease: results of a multicenter, randomized, double-blind, parallel-group controlled
  23. trial,” Respir. Res., vol. 22, no. 1, pp. 1–12, 2021, doi: 10.1186/s12931-021-01740-w.
  24. I. F. Ascar and F. M. Khaleel, “Evaluation of Some Antioxidants and Oxidative Stress Tests in Iraqi
  25. Lung Cancer Patients Abstract :,” vol. 19, no. November, pp. 1466–1470, 2022.
  26. K. Zabłocka-Słowińska et al., “Oxidative stress in lung cancer patients is associated with altered
  27. serum markers of lipid metabolism,” PLoS One, vol. 14, no. 4, 2019, doi: 10.1371/journal.pone.0215246.
  28. Herbst, “Lung cancer Lung cancer Lung cancer,” Conn’s Curr. Ther. 2020, vol. 2030, no. November,
  29. pp. 133–141, 2013.
  30. J. E. Klaunig, “Oxidative Stress and Cancer,” Curr. Pharm. Des., vol. 24, no. 40, pp. 4771–4778,
  31. , doi: 10.2174/1381612825666190215121712.
  32. L. Kennedy, J. K. Sandhu, M. E. Harper, and M. Cuperlovic‐culf, “Role of glutathione in cancer:
  33. From mechanisms to therapies,” Biomolecules, vol. 10, no. 10, pp. 1–27, 2020, doi: 10.3390/biom10101429.
  34. J. Carmichael et al., “Glutathione and related enzyme activity in human lung cancer cell lines,” Br. J.
  35. Cancer, vol. 58, no. 4, pp. 437–440, 1988, doi: 10.1038/bjc.1988.236.
  36. E. Cecerska-Heryć, O. Surowska, R. Heryć, N. Serwin, S. Napiontek-Balińska, and B. Dołęgowska,
  37. “Are antioxidant enzymes essential markers in the diagnosis and monitoring of cancer patients – A review,”
  38. Clin. Biochem., vol. 93, no. November 2020, pp. 1–8, 2021, doi: 10.1016/j.clinbiochem.2021.03.008.
  39. A. Nandi, L. J. Yan, C. K. Jana, and N. Das, “Role of Catalase in Oxidative Stress- And AgeAssociated Degenerative Diseases,” Oxid. Med. Cell. Longev., vol. 2019, 2019, doi: 10.1155/2019/9613090.
  40. A. Mussa et al., “High-Dose Vitamin C for Cancer Therapy,” Pharmaceuticals, vol. 15, no. 6, 2022,
  41. doi: 10.3390/ph15060711.
  42. A. Mohan et al., “Impact of chemotherapy on symptom profile, oxidant-antioxidant balance and
  43. nutritional status in non-small cell Lung Cancer,” Lung India, vol. 34, no. 4, pp. 336–340, 2017, doi:
  44. 4103/0970-2113.209230.
  45. H. Kaynar, M. Meral, H. Turhan, M. Keles, G. Celik, and F. Akcay, “Glutathione peroxidase,
  46. glutathione-S-transferase, catalase, xanthine oxidase, Cu-Zn superoxide dismutase activities, total
  47. glutathione, nitric oxide, and malondialdehyde levels in erythrocytes of patients with small cell and nonsmall cell lung cancer,” Cancer Lett., vol. 227, no. 2, pp. 133–139, 2005, doi: 10.1016/j.canlet.2004.12.005.
  48. Y. Hu, W. Lu, H. Pelicano, and P. Huang, “Novel Action of Paclitaxel against Cancer Cells :
  49. Bystander Effect Mediated by Reactive Oxygen Species,” no. 8, pp. 3512–3517, 2007, doi: 10.1158/0008-
  50. CAN-06-3914.